ArticleOpen medicine (Warsaw, Poland)2026
The causal role of plasma protein ratios in ulcerative colitis: insights from mendelian randomization and single-cell sequencing.
Article in Open medicine (Warsaw, Poland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This Mendelian randomization study aimed to systematically investigate the causal associations of 2,821 plasma protein ratios with UC susceptibility and validate potential biomarkers through multi-omics approaches. Methods: This study employed a two-sample Mendelian randomization (MR) approach using publicly available genetic data from genome-wide association studies (GWAS), with single nucleotide polymorphisms (SNPs) serving as instruments for exposures and outcome variables. Using the two-sample MR approach, we assessed the associations between 2,821 plasma protein ratios and UC and performed a series of sensitivity analyses to enhance the robustness of our findings. Additionally, single-cell sequencing was used to validate and explore the MR results. And ELISA assays were carried to validate the expression of certain protein ratios. Results: The inverse-variance weighted method identified significant relationships between 165 plasma protein ratios and UC (FDR<0.05). UC susceptibility, per one standard deviation increase in genetically predicted protein ratios, ranged from 0.539 (DCTN1/IKBKG, 95 % CI: 0.408-0.712) to 2.078 (CCT5/DCTN1, 95 % CI: 1.607-2.686). Various sensitivity analyses further confirmed the robustness of these causal relationships. Single-cell sequencing further revealed significant differences in DLL1/TGFBR2 ratios between UC and healthy controls (p<0.0001), with a moderate yet significant elevation in CCT5/DCTN1 ratios (p<0.01) and no notable difference in BCR/DCTN1 ratios. Validation using ELISA in 26 pairs of UC patients and healthy controls showed a significantly elevated DLL1/TGFBR2 ratio in the UC group (p<0.001), while CCT5/DCTN1 and BCR/DCTN1 ratios showed no differences. Conclusions: The findings reveal a robust causal relationship between the DLL1/TGFBR2 plasma protein ratio and UC, offering novel insights into the diagnosis and treatment of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.